Pathspeed workstation

Multiparametric MRI (mpMRI) was performed using a 3T scanner (Intera Archieva TX or Ingenia, Philips Medical Systems) with a phased-array body coil. MRI protocols are summarized in Supplementary Table 1. MRI scans consisted of T2-weighted (T2W) MRI in the axial and sagittal planes, axial DW MRI with the highest b-value of 1500 s/mm², and axial dynamic contrast-enhanced (DCE) MRI. The ADC map was generated from the DW MRI data with b-values of 0, 100, and 1000 s/mm² through a mono-exponential fit. DCE MRI was performed immediately after a bolus injection of gadopentetate dimeglumine (Magnevist, Bayer Schering Pharma) or gadobutrol (Gadovist, Bayer Schering Pharma) (dose: 0.1 mmoL/kg; rate: 2–3 mL/s) using a power injector, followed by a 20 mL saline flush. Prior to the MRI scan, 20 mg of hyoscine butylbromide (Buscopan, Boehringer Ingelheim) was administered as an intramuscular injection to reduce bowel peristalsis. However, it was not administered in patients with myasthenia gravis, glaucoma, cardiac arrhythmia, severe urinary retention, or obstructive ileus (16 patients in our study; 9 due to glaucoma and 7 due to arrhythmia). Subtraction DCE images were generated from the data pertaining to post-contrast and precontrast enhanced images, to assess the actual prostatic enhancement. All MR images were archived using PACS (PathSpeed Workstation, GE Healthcare) for image analyses.